We performed spatial transcriptomics of estrogen receptor (ER)–negative, ER-low, and ER-high tumor regions of breast cancers that were intermediate (10%-60%) ER ...
The majority of patients with advanced NSCLC do not respond to monotherapy with PD-1 axis inhibition, and more robust predictive biomarkers are needed. In this study, we assessed tumor samples from 67 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results